AstraZeneca Pharma India Limited

NSE ASTRAZEN.NS

AstraZeneca Pharma India Limited Return on Assets (ROA) for the year ending March 31, 2024: 14.98%

AstraZeneca Pharma India Limited Return on Assets (ROA) is 14.98% for the year ending March 31, 2024, a 48.61% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

AstraZeneca Pharma India Limited Return on Assets (ROA) for the year ending March 31, 2023 was 10.08%, a 40.18% change year over year.
AstraZeneca Pharma India Limited Return on Assets (ROA) for the year ending March 31, 2022 was 7.19%, a -40.29% change year over year.
AstraZeneca Pharma India Limited Return on Assets (ROA) for the year ending March 31, 2021 was 12.04%, a 17.81% change year over year.
AstraZeneca Pharma India Limited Return on Assets (ROA) for the year ending March 31, 2020 was 10.22%, a 5.48% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NSE: ASTRAZEN.NS

AstraZeneca Pharma India Limited

CEO	Dr. Sanjeev Kumar Panchal
IPO Date	July 1, 2002
Location	India
Headquarters	Manyata Embassy Business Park
Employees	940
Sector	Health Care
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Key trends

Past 5 years